Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III
18 septembra, 2020 8:01 pmAuthors: Christian Carrie, Nicolas Magné, Patricia Burban-Provost, et. al. Abstract: 5001 Clinical Trial Registry Number: NCT00423475 Citation:...
Novel Targeted-Antibody Treatment Produced Responses in Nearly Half of Patients with Advanced Urothelial Cancer
18 septembra, 2020 8:01 pmJune 3, 2019 “If advanced urothelial cancer progresses following treatment with platinum-based chemotherapy and immunotherapy with checkpoint inhibitors there are...
SPRÁVA Z VÝROČNEJ KONFERENCIE AMERICKEJ ONKOLOGICKEJ SPOLOČNOSTI 2019 Genitourinárne malignity
18 septembra, 2020 8:01 pmV dňoch 1. – 5. júna 2019 sa v americkom Chicagu uskutočnila výročná konferencia Americkej onkologickej spoločnosti (ASCO®). Aj tento rok odzneli...
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab
18 septembra, 2020 8:01 pmAuthors: Michael E. Hurwitz, Daniel C. Cho, Arjun Vasant Balar, et. al. Abstract: 2623 Clinical Trial Registry Number:...
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO)
18 septembra, 2020 8:00 pmAuthors: Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, et. al. Abstract: 9582 Citation: J Clin Oncol 37, 2019 (suppl;...
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma
18 septembra, 2020 8:00 pmAuthors: Paul D. Nathan, Caroline Robert, Jean Jacques Grob, et. al. Abstract: 9507 Clinical Trial Registry Number: NCT01584648;...
ASCO® 2019 – malígny melanóm Opäť krok dopredu
18 septembra, 2020 8:00 pmMalígny melanóm bol roky v úzadí pri hodnotení príchodu nových metód terapie a inovatívnych preparátov. Len pred niekoľkými rokmi sa situácia obrátila...
Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24
18 septembra, 2020 8:00 pmAuthors: Mansoor Raza Mirza, Elisabeth Avall-Lundqvist, Michael J. Birrer, et. al. Abstract: 5505 Clinical Trial Registry Number: NCT02354131...
Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994
18 septembra, 2020 8:00 pmAuthors: Gemma Kenter, Stefano Greggi, Ignace Vergote, et. al. Abstract: 5503 Clinical Trial Registry Number: NCT00039338 Citation:...
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial
18 septembra, 2020 8:00 pmAuthors: Matthew A. Powell, Virginia L. Filiaci, Martee Leigh Hensley, et. al. Abstract: 5500 Clinical Trial Registry Number:...